AI MARKET SCANNING

Cogent Biosciences, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +8.94%
MAX GAP RECORD +121.05%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $COGT
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 10, 2026 Earnings Release 2026-08-10 (UNDETERMINED)
+0.00%
May 05, 2026 Earnings Release 2026-05-05 (BEFORE OPEN)
+0.52%
Feb 17, 2026 Earnings Release 2026-02-17 (BEFORE OPEN)
+0.00%
Nov 07, 2025 Earnings Release 2025-11-07 (AFTER CLOSE)
+121.05%
Aug 05, 2025 Earnings Release 2025-08-05 (BEFORE OPEN)
-0.25%
May 06, 2025 Earnings Release 2025-05-06 (BEFORE OPEN)
-1.80%
Feb 25, 2025 Earnings Release 2025-02-25 (BEFORE OPEN)
-0.27%
Nov 12, 2024 Earnings Release 2024-11-12 (BEFORE OPEN)
-1.73%

VOLATILITY & GAP BIAS

AVG GAP MOVE 10.6%
Bullish Gaps (4)
Bearish Gaps (5)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $COGT

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis,…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗